A phase IIb multicentric controlled study evaluating the therapeutic vaccine TG4010(MVA-MUC1-IL2) as an adjunct to standard chemotherapy in advanced non small cell lung cancer.

Trial Profile

A phase IIb multicentric controlled study evaluating the therapeutic vaccine TG4010(MVA-MUC1-IL2) as an adjunct to standard chemotherapy in advanced non small cell lung cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2015

At a glance

  • Drugs TG 4010 (Primary) ; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Transgene
  • Most Recent Events

    • 07 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Oct 2011 Results published in The Lancet, according to a Transgene media release.
    • 17 Jun 2009 Results have been reported by Transgene in a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top